Our Strategy
We are developing a scalable infrastructure that enables the rapid and efficient provision of clinically applicable phages. This pipeline supports the identification, characterization, and preparation of phages for safe use in humans, tailored to specific clinical applications. At the same time, we are establishing the framework for controlled clinical trials to position phage therapy as a novel and targeted therapeutic option.
With this dual strategy - intensive fundamental research at ZIP and clinical implementation through BayPha - we are laying the foundation for an innovative and forward-looking approach to combat multidrug-resistant infections.